STAT Reports

The 20 Executives — and Companies — to Know in Chinese Biotech

$499.00

The 20 Executives — and Companies — to Know in Chinese Biotech
License Type:

In China, biotechnology long lagged behind the industry in the West. Now, thanks to billions of dollars in state and private investment — and dramatic regulatory changes — what took a half century of iteration in the U.S. has happened over the course of about 20 years in China. The results are astounding, with China now developing treatments and generics that rival the best efforts of the drug industry’s incumbents. 

In this latest STAT Report, a collaboration between STAT and The Wire, a news and data analytics company focused on China, we feature the 20 most important executives leading this revolution in Chinese drug development. Their stories track China's evolution in the global market for new therapies. And, as a result, this report helps tell the story of some of the industry’s hottest companies.

Highlights include:

  • A brief overview of the growth of China’s biotech industry 
  • Profiles of 20 of the most important Chinese biotech executives
  • Snapshots of their companies -- including annual revenue and market cap

How it works

Add this report to your cart, and then complete the checkout process. Once you have, you'll receive an email with the link to download the full report file. This report is digital-only, so you will not receive a printout.

Preview

Take a peek at what's included in this report.